| Researchers at Fox Chase Cancer Center conducted the largest published, peer-reviewed, study to-date examining the short-term adverse effects of mRNA COVID-19 vaccination in patients with cancer—finding they experienced no more, and no different, side effects compared to non-cancer patients.
PLYMOUTH MEETING, Pa., Feb. 7, 2022 /PRNewswire/ — New research in the February 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network confirms that mRNA vaccine for COVID-19 are just as safe for people with cancer as they are for cancer-free individuals. Researchers from Fox Chase Cancer Center tracked short-term side-effects from more than 1,753 recipients of the Pfizer BNT162b2 vaccine, and found no additional reactions for patients undergoing active cancer treatment (surgery, chemotherapy, immunotherapy, or radiation therapy) or who had completed treatment. “Patients, their families, and their medical caregivers, should absolutely find these results reassuring. We surveyed almost 2,000 patients and found that cancer patients aren’t at risk for any unexpected reactions to being vaccinated compared to people without cancer,” said Eric M. Horwitz, MD, FABS, FASTRO, lead researcher and chair of the Department of Radiation Oncology, Lewis Katz School of Medicine at Temple University. “We now have the data and the clinical experience from thousands and thousands and thousands of cancer patients who have been vaccinated. We know that the mRNA vaccines are safe and are absolutely the most effective way to prevent hospitalization and death from COVID-19.” The results come from in person, phone and online surveys given to people who received two doses of the mRNA vaccine, three weeks apart, between February 16 and May 15, 2021. 1,183 people with a history of cancer responded to both surveys, with 17.8% then currently undergoing treatment. Respondents experienced pain at the injection site, muscle pain, joint pain, fever, chills, headache, nausea, and fatigue at similar rates as those reported by people without cancer from the original clinical trials. Adverse effects for people undergoing immunotherapy also mirrored those in the general population. “It’s crucial that cancer patients get vaccinated against COVID-19 because we know they can be particularly vulnerable to infection and its consequences, but some people have expressed concerns about possible reactions from the vaccines,” continued Dr. Horwitz. “Before this study, there wasn’t a lot of data specifically on the cancer population so we made sure to collect and report this information to help both patients and physicians make informed decisions to get mRNA vaccines.” “Getting vaccinated against COVID-19 was an opportunity for me to take control and help protect myself,” said Dan Burkus, who has received treatment from Fox Chase Cancer Center. “Undergoing cancer treatment and follow-up can be terrifying, especially during a pandemic. This new proof that people with cancer won’t have any extra side-effects from the mRNA vaccines is one less thing to worry about and one more reason to get the shot.” “The investigators convincingly showed no greater incidence of side-effects in patients with a history of cancer, and in fact recipients with a history of cancer had lower rates of pain at the injection site,” commented Natalie Callander, MD, University of Wisconsin Carbone Cancer Center, a member of the NCCN Advisory Committee on COVID-19 Vaccination and Pre-exposure Prophylaxis who was not involved in this research. “Over half the patients in this large prospective study had a history of cancer and about 18% were on active treatment. This study demonstrates that cancer patients experience no greater rate of complications and should help to counteract misinformation about COVID-19 vaccinations. This report provides additional reassurance to practitioners and patients that COVID-19 vaccines are safe and should be offered without hesitation, in accordance with CDC and NCCN recommendations.” To read the entire study, visit JNCCN.org. Complimentary access to “Adverse Events Reported by Patients With Cancer After Administration of a 2-Dose mRNA COVID-19 Vaccine” is available until May 10, 2022. Visit NCCN.org/covid-19 for more information on COVID-19 and cancer, including the latest recommendations from the NCCN Advisory Committee on COVID-19 Vaccination and Pre-exposure Prophylaxis. About JNCCN—Journal of the National Comprehensive Cancer Network More than 25,000 oncologists and other cancer care professionals across the United States read JNCCN—Journal of the National Comprehensive Cancer Network. This peer-reviewed, indexed medical journal provides the latest information about innovation in translational medicine, and scientific studies related to oncology health services research, including quality care and value, bioethics, comparative and cost effectiveness, public policy, and interventional research on supportive care and survivorship. JNCCN features updates on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), review articles elaborating on guidelines recommendations, health services research, and case reports highlighting molecular insights in patient care. JNCCN is published by Harborside. Visit JNCCN.org. To inquire if you are eligible for a FREE subscription to JNCCN, visit NCCN.org/jnccn/subscribe. Follow JNCCN on Twitter @JNCCN. About the National Comprehensive Cancer Network Logo – https://mma.prnewswire.com/media/441768/NCCN_Logo.jpg |
(Disclaimer: The above press release comes to you under an arrangement with PRNewswire India and this publication takes no editorial responsibility for the same.)